Only 12.5% (2/16) and 18.75% (3/16) had a positive CD4+ and CD8+ cellular and humoral response, respectively; however, 68.75% (11/16) and 100% (16/16) of them elicited a CD4+ and CD8+ TCM lymphocyte response, respectively (Figure 4 B-NHL). The gene discussed is CD4; the disease is non-Hodgkin lymphoma.